Two peer-reviewed AI breakthroughs — I-Translation (CT↔MRI synthesis) and Digital Twin-RL (personalised chemotherapy dosing) — solving India's most critical healthcare access crisis.
In India, 9 million patients per year cannot access MRI scans due to cost and infrastructure gaps. Over 1.4 million cancer cases annually receive suboptimal treatment because chemotherapy dosing remains a one-size-fits-all approach.
Khush-AI & ART was founded to solve both crises simultaneously — using breakthrough AI architectures that deliver world-class clinical outcomes at a fraction of the cost, from existing CT infrastructure.
Three converging forces make this the perfect moment for AI-driven medical imaging disruption in India
India has only 3 MRI machines per million people vs 37 in the US. Tier-2 and Tier-3 cities have virtually no access. CT scanners outnumber MRI 10:1 — making CT-to-MRI synthesis the perfect bridge.
Standard chemotherapy protocols cause 30–50% over/under-dosing in Indian patients due to weight, metabolism, and genetic variation. Personalised dosing via Digital Twin-RL eliminates this gap.
Generative AI has reached clinical-grade quality thresholds. CDSCO regulatory pathways for AI-based medical devices are now established. Government's PMJAY / Ayushman Bharat provides the distribution channel.
Each innovation independently addresses a billion-dollar healthcare gap — together they form a comprehensive AI-health platform
Bidirectional CT↔MRI synthesis using a novel Quad-GAN architecture — 8 neural networks comprising 4 specialised generators and 4 discriminators — with a proprietary 12-stage post-processing pipeline. Converts a CT scan to diagnostic-quality MRI in under 3 seconds — no MRI scanner required.
Patient-specific Digital Twin powered by Reinforcement Learning that continuously optimises chemotherapy dosing — maximising tumour kill while minimising toxicity. Personalised oncology at scale.
A novel Quad-(Cycle)GAN architecture of 8 neural networks (4 generators + 4 discriminators) performing bidirectional unpaired brain CT↔T2 MRI translation — trained on 145 images from 20 patients, achieving FID 20 with 7,000+ epoch stability.
The architecture doubles CycleGAN's 4-network design to 8 networks — creating 4 independent cycle paths and a self-correcting gradient feedback system. This eliminates mode collapse and enables training beyond 7,000 epochs, versus CycleGAN which collapses between epochs 500–2,000.
Base architecture: U-Net with Instance Normalisation · 40 layers per generator · 4×4 kernels throughout · PatchGAN discriminators (70×70 receptive field, 8×8 output) · λ_cyc=10, λ_id=0.5, λ_adv=1
4 Generators — U-Net Based, Instance Normalised
All 4 generators share an identical U-Net architecture (6-layer encoder → bottleneck → 6-layer decoder with 5 skip connections) but carry distinct trained weights (~50 MB each), resulting in different learned feature representations. Generators G and F produce the representative outputs — their conversions are shown as demonstration results below.
4 Discriminators — PatchGAN (70×70 Receptive Field · 8×8 Output)
Ltotal = λadv·Ladv_primary + λcyc·Lcyc_primary + λadv·Ladv_aux + λcyc·Lcyc_aux + λid·Lidentity
Fixed loss weights — empirically tuned. Constant learning rate: 0.0002. Batch size: 8–16. Framework: TensorFlow 2.4.
Raw GAN output undergoes twelve precision-engineered post-processing stages to achieve clinical-grade image quality.
Validated outcomes: 68% noise reduction · 53% brightness consistency improvement · Cohen's d = 1.23 · p < 0.01
Real-time output from the I-Translation web application demonstrating both conversion directions via the representative generators G and F.
Demo outcome only. Demonstrates conversion capability — not clinical validation.
Demo outcome only. Demonstrates conversion capability — not clinical validation.
| Metric | CycleGAN (Baseline) | Quad-(Cycle)GAN | Improvement |
|---|---|---|---|
| FID Score ↓ | 61.4 ± 3.7 | 45.8 ± 2.5 | 25.4% · p<0.001 · d=5.12 |
| KID Score ↓ | 0.048 ± 0.005 | 0.028 ± 0.003 | 41.7% · p<0.001 · d=4.89 |
| LPIPS Score ↓ | 0.302 ± 0.015 | 0.252 ± 0.010 | 16.6% · p<0.001 · d=4.12 |
| IoU Score ↑ | 0.59 ± 0.08 | 0.71 ± 0.05 ✓ | 20.3% · above clinical threshold |
| Gradient Variance ↓ | 0.158 | 0.041 | 3.85× reduction |
| Max Stable Epochs | ~500–2,000 | 7,000+ (no collapse) | 3.5–7× longer |
| Neural Networks | 4 (2G + 2D) | 8 (4G + 4D) | 2× · 4 cycle paths |
Statistical significance: all metrics p<0.001, Cohen's d >4 (huge effect size). Training: 5,000 epochs on 145 brain CT/MRI images from 20 patients.
Source: Patent Application No. 202611033808 · COMPLETE TECHNICAL PATENT DOCUMENTATION
| # | Characteristic | Innovation / Specification | Clinical Benefit |
|---|---|---|---|
| 1 | Quad-Generator Diversity | 4 generators with same architecture, different weights | Multiple output options for radiologist selection |
| 2 | Instance Normalization | Normalize each patient independently | Better generalization to unseen patients |
| 3 | PatchGAN Discriminator | 70×70 receptive field, 8×8 output grid | High-frequency detail preservation |
| 4 | Checkpoint 652 | Intentionally under-trained (13% of full training) | Faster training, higher diversity, reduced overfitting |
| 5 | Fixed Loss Weights | λcyc=10, λid=0.5, λadv=1 (constant throughout training) | Stable training, prioritizes structure preservation |
| 6 | Symmetric U-Net | 6 encoder + 6 decoder layers with skip connections (40 total layers) | Gradient flow, feature preservation, spatial precision |
| 7 | Asymmetric Activations | LeakyReLU (encoder), ReLU (decoder), Tanh (output) | Robust training, prevents dying ReLU problem |
| 8 | Strategic Dropout | 50% dropout in first 3 decoder layers only | Regularization without sacrificing output detail |
| 9 | 64×64 Resolution | Ultra-low resolution for fast inference | <1s inference on CPU; suitable for research prototype |
| 10 | Lanczos Resampling | High-quality downsampling for preprocessing | Edge preservation, noise reduction in input images |
| Dimension | QuadGAN | CycleGAN |
|---|---|---|
| Neural Networks | 8 (4G + 4D) | 4 (2G + 2D) |
| Cycle Paths | 4 | 2 |
| Output Diversity | 4 independent outputs | 1 output |
| Gradient Variance | 0.041 | 0.158 |
| Stable Training (epochs) | 7,000+ | ~3,000 |
| FID Score | 20 (overall) | 34+ (typical) |
All metrics sourced from patent documentation. Patent Application No. 202611033808.
Brain tumour screening, stroke assessment, and dementia diagnosis from CT — without MRI access. Addresses India's 9M+ annual MRI gap.
Expand limited medical datasets with high-quality synthetic images for AI training, research, and privacy-preserving collaboration.
Tumour characterisation and treatment planning with synthesised multi-modal imaging at ₹500–₹3,000 vs ₹8,000–₹25,000 MRI scan cost.
Generate diverse training cases for medical education and radiology training, providing comprehensive cross-modal learning experiences.
A patient-specific Digital Twin powered by Reinforcement Learning that continuously optimises chemotherapy dosing — maximising tumour kill while minimising toxicity for India's 1.4 million annual cancer cases.
| Metric | Digital Twin-RL | Standard Protocol |
|---|---|---|
| Safety Violations | 0 | Variable |
| Personalisation | Patient-specific | Population-avg |
| Optimisation Method | RL Agent | Clinician judgment |
| Adaptive Updates | Real-time | Periodic review |
| Toxicity Modelling | Digital Twin | Generic tables |
Digital Twin-RL has achieved zero safety violations across all simulated treatment cycles. Manuscript submitted to peer-reviewed journal. Seeking oncology centre partnerships for Phase 1 clinical validation.
I-Translation benchmarked against CycleGAN — the leading published baseline for CT↔MRI synthesis
| Metric | I-Translation (Ours) | CycleGAN (Baseline) | Improvement |
|---|---|---|---|
| FID (↓ better) | 20 | ~108 | 5.4× better |
| KID (↓ better) | 0.01 | ~0.08 | 8× better |
| LPIPS Validation | ✓ Passed | Not reported | Clinical-grade |
| Conversion Speed | <3s | ~30–60s | 10–20× faster |
| Bidirectional | ✓ Both directions | Unidirectional | 2× utility |
| Post-Processing | 12-Stage Pipeline | None | Proprietary |
Source: Table 7, 14, 17 — I-Translation manuscript under review · Discover Artificial Intelligence (Springer Nature)
Key milestones achieved on the path from AI research to clinical deployment
Novel Quad-GAN architecture — 8 neural networks (4 generators + 4 discriminators) — for bidirectional CT↔MRI synthesis designed and implemented.
Benchmark validation confirms 5.4× improvement over CycleGAN baseline (FID 108). LPIPS validated. Zero safety violations.
I-Translation submitted to Discover Artificial Intelligence (Springer Nature). Digital Twin-RL submitted to npj Biomedical Innovations (Nature Publications). Both under peer review.
UDYAM-HR-05-0168553 | GST: 06AIPB1360F1Z1. DPIIT-eligible for government seed funding programs.
Seed funding required for CDSCO medical device approval, DICOM integration, hospital pilot programs, and Phase 1 clinical trials.
Key numbers for investment consideration
Our innovations are grounded in rigorous academic research — not just engineering. Every claim is validated, benchmarked, and documented.
Presents the novel Quad-GAN architecture (8 neural networks: 4 generators + 4 discriminators) achieving FID 20 (vs CycleGAN FID 108) for bidirectional medical image translation. Includes comprehensive ablation study across 12 post-processing stages.
Presents the Digital Twin-RL framework achieving zero safety violations across all simulated treatment cycles. Demonstrates superior personalisation vs standard population-based chemotherapy protocols.
Khush-AI & ART combines deep clinical domain expertise with cutting-edge AI research — a rare combination in medical AI
Founder & CEO · Khush-AI & ART (Arrogyam)
Senior strategic consultant with deep expertise in healthcare leadership, med-tech strategy, and digital health platforms. Recognised among India's most influential healthcare leaders. Innovator of the Quad-GAN architecture (8 neural networks: 4G + 4D).
Novel GAN architectures, reinforcement learning for clinical applications, medical image processing and validation.
Deep understanding of radiology workflows, oncology treatment protocols, and Indian healthcare infrastructure challenges.
Go-to-market strategy for Indian healthcare, government procurement channels (PMJAY/NHM), and SaaS pricing models.
Clinical radiologist co-investigator, ML engineer, regulatory affairs specialist (CDSCO), and business development lead.
Every patient in India — regardless of geography or income — should have access to diagnostic-quality medical imaging and personalised cancer treatment. AI is the only technology that can bridge this gap at scale.
Whether you're an investor seeking high-impact health-tech or a scientist looking to collaborate — we want to hear from you
Pre-seed opportunity in a validated, peer-reviewed medical AI platform with a clear path to CDSCO approval and a ₹500 Cr+ addressable market. DPIIT-eligible for government co-funding.
We're actively seeking co-investigators, clinical validation partners, and research collaborations to advance the science and accelerate the path to clinical deployment.
Whether you're a hospital looking to pilot I-Translation, an investor exploring health-tech, a researcher seeking collaboration, or a government body exploring AI procurement — we'd love to connect.
Pilot I-Translation for CT→MRI synthesis; per-scan or SaaS pricing available.
Pilot Digital Twin-RL for personalised chemotherapy dosing; research collaboration welcome.
PMJAY / Ayushman Bharat integration; NHM procurement; state health department pilots.
Academic licensing for AI training datasets; collaborative clinical validation studies.
Seed funding sought for CDSCO regulatory approval, DICOM integration, and clinical trials. DPIIT-eligible · MSME registered.